TRDA Stock Overview
A clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Entrada Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.93 |
| 52 Week High | US$20.49 |
| 52 Week Low | US$10.75 |
| Beta | -0.27 |
| 11 Month Change | 3.52% |
| 3 Month Change | 11.30% |
| 1 Year Change | 57.83% |
| 33 Year Change | -33.57% |
| 5 Year Change | n/a |
| Change since IPO | -25.14% |
Recent News & Updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Shareholder Returns
| TRDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.2% | -6.5% | -1.0% |
| 1Y | 57.8% | 14.6% | 30.3% |
Return vs Industry: TRDA exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: TRDA exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| TRDA volatility | |
|---|---|
| TRDA Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TRDA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TRDA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 177 | Dipal Doshi | www.entradatx.com |
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Entrada Therapeutics, Inc. Fundamentals Summary
| TRDA fundamental statistics | |
|---|---|
| Market cap | US$629.15m |
| Earnings (TTM) | US$54.95m |
| Revenue (TTM) | US$215.23m |
11.6x
P/E Ratio2.9x
P/S RatioIs TRDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRDA income statement (TTM) | |
|---|---|
| Revenue | US$215.23m |
| Cost of Revenue | US$120.19m |
| Gross Profit | US$95.04m |
| Other Expenses | US$40.09m |
| Earnings | US$54.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.55 |
| Gross Margin | 44.16% |
| Net Profit Margin | 25.53% |
| Debt/Equity Ratio | 0% |
How did TRDA perform over the long term?
See historical performance and comparison